Therapy for Early COVID-19: A Critical Need

In this Viewpoint, Fauci and NIAID colleagues review leading candidates for treatment of mild to moderate coronavirus disease 2019 (COVID-19) to prevent disease progression and longer-term complications, including emerging antiviral drugs, immune-modulating agents, and antibody-based therapies, and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JAMA : the journal of the American Medical Association 2020-12, Vol.324 (21), p.2149-2150
Hauptverfasser:	Kim, Peter S, Read, Sarah W, Fauci, Anthony S
Format:	Artikel
Sprache:	eng
Schlagworte:	Adaptive Clinical Trials as Topic Antibodies Antiviral agents Antiviral Agents - therapeutic use Complications Coronaviruses COVID-19 COVID-19 - therapy Drug development Drug Discovery Humans Immunomodulation Immunosuppressive agents Medical treatment Pandemics Randomized Controlled Trials as Topic Viral diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In this Viewpoint, Fauci and NIAID colleagues review leading candidates for treatment of mild to moderate coronavirus disease 2019 (COVID-19) to prevent disease progression and longer-term complications, including emerging antiviral drugs, immune-modulating agents, and antibody-based therapies, and the challenges of developing randomized trials to rapidly evaluate the safety and efficacy of each.
ISSN:	0098-7484 1538-3598
DOI:	10.1001/jama.2020.22813